[Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
Ringe
J D
JD
Westdeutsches Osteoporose Zentrum, Medizinische Klinik 4, Klinikum Leverkusen, 51375, Leverkusen, Germany. ringe@klinikum-lev.de
Nitschmann
S
S
D000368:Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D007262:Infusions, Intravenous; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid